Background: RAD001®, an oral inhibitor of the mammalian target of rapamycin (mTOR) that
has shown anti-tumor activity both as single-agent and in combination with other anticancer …

Background Non-small cell lung cancer (NSCLC) is a leading cause of cancer death
worldwide. Ramucirumab plus docetaxel became one of the available options for …

8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …

Introduction: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …

Introduction EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo
(PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for …

Background Blocking vascular endothelial growth factor receptor (VEGFR) pathway can
enhance the efficacy of EGFR-TKI in EGFRm NSCLC. ACTIVE is the first phase III study …

Background Bevacizumab and erlotinib target different tumour growth pathways with little
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …

Background A retrospective analysis of clinical data were conducted reviewing patients who
were given erlotinib at Peking Union Medical College (PUMC) Hospital from May 2005 to …

BACKGROUND• Many patients with advanced non–small cell lung cancer (NSCLC) initially
benefit from treatment with anti–epidermal growth factor receptor (EGFR) tyrosine kinase …

Erlotinib is a potent reversible HER1/epidermal growth factor receptor tyrosine kinase
inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this …